サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541719

抗真菌薬市場レポート：薬剤クラス別、適応症別、地域別、2024～2032年

Antifungal Drugs Market Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 147 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗真菌薬市場レポート：薬剤クラス別、適応症別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗真菌薬市場規模は2023年に151億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて3.1%の成長率（CAGR）を示し、2032年には201億米ドルに達すると予測しています。

抗真菌薬（抗真菌剤）は、皮膚、毛髪、爪の真菌感染症の治療に使用される医薬品を指します。一般的に使用される抗真菌薬には、ポリエン系、アゾール系、アリルアミン系などがあります。これらは、カンジダやサナダムシなどの真菌や皮膚糸状菌を中和し、水虫、白癬、アスペルギルス症、カンジダ症、真菌性髄膜炎の治療を助ける。これらの薬剤は、市販薬（OTC）として、カプセル剤、ゲル剤、液剤、錠剤、または真菌感染を最小限に抑え、予防するために血流に直接注入する静脈注射液が一般的に販売されています。

抗真菌薬市場傾向

真菌感染症や院内感染症の流行が増加していることは、市場成長に明るい展望をもたらす重要な要因のひとつです。抗真菌薬は、病院内の汚染された表面や湿度の高い環境にさらされることで発症する全身性と表在性の感染症の両方に有効です。さらに、都市部でも農村部でも市販薬が手軽に入手できることが、市場成長の原動力となっています。大衆の健康意識が高まるにつれ、軽度の感染症を適時に治療するためにOTC治療を選ぶ消費者が増えています。さらに、侵襲性真菌感染症の治療用の合成と半合成アゾール系化合物の開発など、さまざまな製品革新も成長を促す要因となっています。また、製薬メーカー各社は、スプレー、クリーム、錠剤、注射剤など、有効性を高めた新規治療の研究開発（R&D）にも積極的に投資しています。製薬業界の著しい成長、公衆衛生を促進する政府の有利な政策の実施など、その他の要因も市場の成長を後押しすると予想されます。

本レポートで扱う主要質問

  • 2023年の世界の抗真菌薬市場の市場規模は？
  • 2024～2032年の世界の抗真菌薬市場の予想成長率は？
  • 世界の抗真菌薬市場に対するCOVID-19の影響は？
  • 世界の抗真菌薬市場を牽引する主要因は何か？
  • 抗真菌薬市場の薬剤クラス別内訳は？
  • 抗真菌薬市場の世界における適応症別内訳は？
  • 世界の抗真菌薬市場における主要地域は？
  • 世界の抗真菌薬市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の抗真菌薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • アゾール
    • 市場動向
    • 主要セグメント
      • ボリコナゾール（ブイフェンド）
      • ポサコナゾール（ノキサフィル）
      • クロトリマゾール（カネステン）
      • イサブコナゾール（クレセンバ）
      • その他
    • 市場予測
  • エキノキャンディン
    • 市場動向
    • 主要セグメント
      • カスポファンギン（カンシダス）
      • ミカファンギン（ミカミン/ファンガード）
      • その他
    • 市場予測
  • ポリエン
    • 市場動向
    • 主要セグメント
      • アンホテリシン（アムビソーム）
      • その他
    • 市場予測
  • アリルアミン
    • 市場動向
    • 主要セグメント
      • テルビナフィン（ラミシール）
      • その他
    • 市場予測
  • その他

第7章 市場内訳：適応症別

  • 皮膚糸状菌症
  • アスペルギルス症
  • カンジダ症
    • 市場動向
    • 主要セグメント
      • 侵襲性カンジダ症
      • 外陰膣カンジダ症（VVC）
      • 口・喉・食道カンジダ症
      • その他
    • 市場予測
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Arcadia Consumer Healthcare Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Scynexis Inc.
図表

List of Figures

  • Figure 1: Global: Antifungal Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antifungal Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antifungal Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antifungal Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Antifungal Drugs Market: Breakup by Indication (in %), 2023
  • Figure 6: Global: Antifungal Drugs Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Antifungal Drugs (Azoles) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Antifungal Drugs (Azoles) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Antifungal Drugs (Echinocandins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Antifungal Drugs (Echinocandins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Antifungal Drugs (Polyenes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Antifungal Drugs (Polyenes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Antifungal Drugs (Allylamines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Antifungal Drugs (Allylamines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Antifungal Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Antifungal Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Antifungal Drugs (Dermatophytosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Antifungal Drugs (Dermatophytosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Antifungal Drugs (Aspergillosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Antifungal Drugs (Aspergillosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Antifungal Drugs (Candidiasis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Antifungal Drugs (Candidiasis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Antifungal Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Antifungal Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia-Pacific: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia-Pacific: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Antifungal Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Antifungal Drugs Market: Breakup by Country (in %), 2023
  • Figure 73: Middle East and Africa: Antifungal Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Global: Antifungal Drugs Industry: SWOT Analysis
  • Figure 75: Global: Antifungal Drugs Industry: Value Chain Analysis
  • Figure 76: Global: Antifungal Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antifungal Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antifungal Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Antifungal Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Antifungal Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Antifungal Drugs Market: Competitive Structure
  • Table 6: Global: Antifungal Drugs Market: Key Players
目次
Product Code: SR112024A3933

The global antifungal drugs market size reached US$ 15.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.

Antifungal drugs, or antimycotic drugs, refer to the pharmaceutical medicines used for the treatment of fungal infections on skin, hair and nails. Some of the commonly used antifungal drugs include polyenes, azoles and allylamines. They specifically neutralize fungal agents and dermatophytes, such as candida and tapeworms, and aid in the treatment of athlete's foot, ringworm, aspergillosis, candidiasis and fungal meningitis. These drugs are commonly available in over the counter (OTC) capsule, gel, liquid and pill variants or intravenous solutions that are injected directly into the bloodstream to minimize and prevent fungal infection.

Antifungal Drugs Market Trends:

The increasing prevalence of fungal and nosocomial infections is one of the key factors creating a positive outlook for the market growth. Antifungal drugs are effective against both systemic and superficial infections that are acquired from exposure to contaminated surfaces in hospitals or humid conditions. Moreover, the convenient availability of OTC drugs in both urban and rural areas is providing a thrust to the market growth. With the rising health consciousness among the masses, consumers are increasingly opting for OTC therapeutics to timely treat minor infections. Additionally, various product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, are acting as other growth-inducing factors. Pharmaceutical manufacturers are also investing extensively in the research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets and injections with enhanced efficacy. Other factors, including significant growth in the pharmaceutical industry, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antifungal drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class and indication.

Breakup by Drug Class:

Azoles

Voriconazole (Vfend)

Posaconazole (Noxafil)

Clotrimazole (Canesten)

Isavuconazole (CRESEMBA)

Others

Echinocandins

Caspofungin (Cancidas)

Micafungin (Mycamine/ Funguard)

Others

Polyenes

Amphotericin (AmBisome)

Others

Allylamines

Terbinafine (Lamisil)

Others

Others

Breakup by Indication:

Dermatophytosis

Aspergillosis

Candidiasis

Invasive Candidiasis

Vulvovaginal Candidiasis (VVC)

Mouth/Throat/Esophageal Candidiasis

Others

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc., Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Scynexis Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global antifungal drugs market in 2023?
  • 2. What is the expected growth rate of the global antifungal drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global antifungal drugs market?
  • 4. What are the key factors driving the global antifungal drugs market?
  • 5. What is the breakup of the global antifungal drugs market based on the drug class?
  • 6. What is the breakup of the global antifungal drugs market based on the indication?
  • 7. What are the key regions in the global antifungal drugs market?
  • 8. Who are the key players/companies in the global antifungal drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antifungal Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Azoles
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Voriconazole (Vfend)
      • 6.1.2.2 Posaconazole (Noxafil)
      • 6.1.2.3 Clotrimazole (Canesten)
      • 6.1.2.4 Isavuconazole (CRESEMBA)
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Echinocandins
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Caspofungin (Cancidas)
      • 6.2.2.2 Micafungin (Mycamine/ Funguard)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast
  • 6.3 Polyenes
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Amphotericin (AmBisome)
      • 6.3.2.2 Others
    • 6.3.3 Market Forecast
  • 6.4 Allylamines
    • 6.4.1 Market Trends
    • 6.4.2 Key Segments
      • 6.4.2.1 Terbinafine (Lamisil)
      • 6.4.2.2 Others
    • 6.4.3 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Dermatophytosis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Aspergillosis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Candidiasis
    • 7.3.1 Market Trends
    • 7.3.2 Key Segments
      • 7.3.2.1 Invasive Candidiasis
      • 7.3.2.2 Vulvovaginal Candidiasis (VVC)
      • 7.3.2.3 Mouth/Throat/Esophageal Candidiasis
      • 7.3.2.4 Others
    • 7.3.3 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Arcadia Consumer Healthcare Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Astellas Pharma Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bayer AG
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 GlaxoSmithKline Plc
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Merck & Co. Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Merck KGaA
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sanofi S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Scynexis Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials